Interim estimates of 2018/19 vaccine effectiveness against influenza A(H1N1)pdm09, Canada, January 2019.
Adolescent
Adult
Aged
Canada
/ epidemiology
Case-Control Studies
Child
Child, Preschool
Female
Hemagglutination Inhibition Tests
Humans
Infant
Influenza A Virus, H1N1 Subtype
/ genetics
Influenza Vaccines
/ administration & dosage
Influenza, Human
/ epidemiology
Male
Middle Aged
Nasopharynx
/ virology
Nose
/ virology
Outcome Assessment, Health Care
Real-Time Polymerase Chain Reaction
Seasons
Sensitivity and Specificity
Sentinel Surveillance
Sequence Analysis, DNA
Vaccination
/ statistics & numerical data
Vaccine Potency
Canada
ILI
epidemiology
genomics
immunisation
influenza
influenza virus
influenza-like illness
laboratory
vaccine effectiveness
vaccine-preventable diseases
vaccines
viral infections
Journal
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
ISSN: 1560-7917
Titre abrégé: Euro Surveill
Pays: Sweden
ID NLM: 100887452
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
entrez:
31
1
2019
pubmed:
31
1
2019
medline:
28
7
2020
Statut:
ppublish
Résumé
Using a test-negative design, the Canadian Sentinel Practitioner Surveillance Network assessed interim 2018/19 vaccine effectiveness (VE) against predominant influenza A(H1N1)pdm09 viruses. Adjusted VE was 72% (95% confidence interval: 60 to 81) against medically attended, laboratory-confirmed influenza A(H1N1)pdm09 illness. This substantial vaccine protection was observed in all age groups, notably young children who appeared to be disproportionately affected. Sequence analysis identified heterogeneity in emerging clade 6B.1 viruses but no dominant drift variant.
Identifiants
pubmed: 30696523
doi: 10.2807/1560-7917.ES.2019.24.4.1900055
pmc: PMC6351998
doi:
Substances chimiques
Influenza Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Philos Trans R Soc Lond B Biol Sci. 2001 Dec 29;356(1416):1871-6
pubmed: 11779386
PLoS One. 2011;6(10):e25848
pubmed: 22022458
PLoS Pathog. 2013;9(5):e1003354
pubmed: 23671418
Euro Surveill. 2014 Feb 06;19(5):null
pubmed: 24524234
J Virol. 2015 May;89(10):5427-40
pubmed: 25741011
J Infect Dis. 2015 Sep 1;212(5):726-39
pubmed: 25784728
Euro Surveill. 2016;21(11):30168
pubmed: 27020673
Lancet Infect Dis. 2016 Aug;16(8):942-51
pubmed: 27061888
Nat Microbiol. 2016 May 23;1(6):16058
pubmed: 27572841
J Infect Dis. 2017 Dec 19;216(12):1487-1500
pubmed: 29029166
Euro Surveill. 2018 Feb;23(5):
pubmed: 29409570